NO994903L - Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer - Google Patents
Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorerInfo
- Publication number
- NO994903L NO994903L NO994903A NO994903A NO994903L NO 994903 L NO994903 L NO 994903L NO 994903 A NO994903 A NO 994903A NO 994903 A NO994903 A NO 994903A NO 994903 L NO994903 L NO 994903L
- Authority
- NO
- Norway
- Prior art keywords
- prophylaxis
- estrogen receptor
- selective estrogen
- treatment
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for behandling eller profylakse av benign prostatahyperplasi eller prostatakreft hos en pasient som trenger slik behandling som innbefatter administrering av en selektiv østrogenreseptor- moduleringsforbindelse med formel (I), hvori R' og R^ uavhengig er hydroksy og alkoksy med 1 til 4 karbonatomer; og R' og R" er uavhengig metyl eller etyl, eller R' og R'', sammen med nitrogenatomet som de er bundet til danner en pyrrolidino, metyl- pyrrolidino, dimetylpyrrolidino, piperidino, morfolino eller heksametylenimino ring.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4322397P | 1997-04-09 | 1997-04-09 | |
PCT/US1998/007274 WO1998045288A1 (en) | 1997-04-09 | 1998-04-07 | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
NO994903D0 NO994903D0 (no) | 1999-10-08 |
NO994903L true NO994903L (no) | 1999-12-09 |
Family
ID=21926126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO994903A NO994903L (no) | 1997-04-09 | 1999-10-08 | Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0975629A4 (no) |
JP (1) | JP2001518900A (no) |
KR (1) | KR20010006218A (no) |
CN (1) | CN1259944A (no) |
AU (1) | AU6966198A (no) |
BR (1) | BR9808515A (no) |
CA (1) | CA2286204A1 (no) |
EA (1) | EA199900914A1 (no) |
HU (1) | HUP0003589A3 (no) |
ID (1) | ID24358A (no) |
IL (1) | IL132277A0 (no) |
NO (1) | NO994903L (no) |
PL (1) | PL336205A1 (no) |
TR (1) | TR199902701T2 (no) |
WO (1) | WO1998045288A1 (no) |
ZA (1) | ZA982819B (no) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6610706B1 (en) | 1999-07-29 | 2003-08-26 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
US6653479B1 (en) | 1999-07-29 | 2003-11-25 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride |
WO2002089801A1 (en) * | 2001-05-10 | 2002-11-14 | Cedars Sinai Medical Center | Use of benzothiophenes to treat and prevent prostave cancer |
US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
WO2007135547A2 (en) * | 2006-05-22 | 2007-11-29 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
NZ585389A (en) | 2007-10-16 | 2011-10-28 | Repros Therapeutics Inc | Trans-clomiphene for metabolic syndrome |
CA2865234A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
WO2014130310A1 (en) | 2013-02-19 | 2014-08-28 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
CN108348605B (zh) | 2015-11-10 | 2023-06-09 | 帕拉卡林治疗公司 | 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5429922A (en) * | 1988-03-09 | 1995-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for distinguishing virulent and non-virulent toxoplasma infections |
JP3989569B2 (ja) * | 1995-02-28 | 2007-10-10 | イーライ リリー アンド カンパニー | ベンゾチオフェン化合物、中間体、組成物および方法 |
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5731342A (en) * | 1996-02-22 | 1998-03-24 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
-
1998
- 1998-04-02 ZA ZA9802819A patent/ZA982819B/xx unknown
- 1998-04-07 IL IL13227798A patent/IL132277A0/xx unknown
- 1998-04-07 TR TR1999/02701T patent/TR199902701T2/xx unknown
- 1998-04-07 JP JP54316898A patent/JP2001518900A/ja active Pending
- 1998-04-07 AU AU69661/98A patent/AU6966198A/en not_active Abandoned
- 1998-04-07 WO PCT/US1998/007274 patent/WO1998045288A1/en not_active Application Discontinuation
- 1998-04-07 BR BR9808515-8A patent/BR9808515A/pt not_active Application Discontinuation
- 1998-04-07 EP EP98915488A patent/EP0975629A4/en not_active Withdrawn
- 1998-04-07 PL PL98336205A patent/PL336205A1/xx unknown
- 1998-04-07 CN CN98805956A patent/CN1259944A/zh active Pending
- 1998-04-07 KR KR1019997009298A patent/KR20010006218A/ko not_active Application Discontinuation
- 1998-04-07 HU HU0003589A patent/HUP0003589A3/hu unknown
- 1998-04-07 EA EA199900914A patent/EA199900914A1/ru unknown
- 1998-04-07 CA CA002286204A patent/CA2286204A1/en not_active Abandoned
- 1998-04-07 ID IDW991188A patent/ID24358A/id unknown
-
1999
- 1999-10-08 NO NO994903A patent/NO994903L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR9808515A (pt) | 2001-06-19 |
IL132277A0 (en) | 2001-03-19 |
AU6966198A (en) | 1998-10-30 |
EA199900914A1 (ru) | 2000-04-24 |
CA2286204A1 (en) | 1998-10-15 |
WO1998045288A1 (en) | 1998-10-15 |
JP2001518900A (ja) | 2001-10-16 |
HUP0003589A2 (hu) | 2002-01-28 |
ZA982819B (en) | 1999-10-04 |
ID24358A (id) | 2000-07-13 |
EP0975629A1 (en) | 2000-02-02 |
CN1259944A (zh) | 2000-07-12 |
HUP0003589A3 (en) | 2002-02-28 |
KR20010006218A (ko) | 2001-01-26 |
PL336205A1 (en) | 2000-06-05 |
NO994903D0 (no) | 1999-10-08 |
TR199902701T2 (xx) | 2000-02-21 |
EP0975629A4 (en) | 2001-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO994901L (no) | Behandling av sentralnerveforstyrrelser ved selektive östrogenreseptormodulatorer | |
NZ332762A (en) | Isobutylgaba and its derivatives for the treatment of pain | |
MY125942A (en) | Aminoalkoxy carbazoles for the treatment of cns diseases | |
DE69922216D1 (de) | Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte | |
KR950701317A (ko) | 인돌 유도체(Indole Derivative) | |
BR9807674A (pt) | Inibidores bicìclicos da proteìna farnesil transferase | |
NZ514663A (en) | Indigoid bisindole derivatives for treating solid cancers | |
AU565185B2 (en) | N-phenylbenzamide derivatives | |
AU6350699A (en) | Chemical compounds | |
NO994903L (no) | Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer | |
WO2001081340A3 (en) | Heterocycles that are inhibitors of impdh enzyme | |
NZ313185A (en) | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | |
ATE156839T1 (de) | Neue delta-17 und delta-20 ungesätigte und gesatigte 17--g(b)-substituierte-4-aza-5-g(a)- androstan-3-on verbindungen als inhibitoren von 5-alpha-reductase | |
UA72948C2 (uk) | Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів | |
BR0011865A (pt) | derivados aromáticos e heterocìclicos de fitoteróis e/ou fitostanóis para uso no tratamento e prevenção de doença cardiovascular | |
DE69713273D1 (de) | Verwendung von 3,4-Diphenylchromanen zur Herstellung eines Arzneimittels zur Behandlung bzw. Vorbeugung des Prostatakarzinoms | |
HK1028021A1 (en) | Substituted 2-benzylamino-2-phenyl-acetamide compounds | |
NO20002371L (no) | 2-Arylbenzo[b]tiofener til behandling av østrogen- deprivasjonssyndrom | |
NO994902L (no) | Forebygging av brystkreft ved selektive östrogenreseptormodulatorer | |
ATE22294T1 (de) | Pyrido(3,4-c)psoralene, herstellung, verwendung in der kosmetologie und als arzneimittel und diese enthaltende zubereitungen. | |
AU2002211493A1 (en) | Indole derivatives as pde5-inhibitors | |
YU46302A (sh) | Supstituisani piroli | |
NZ502537A (en) | Androst-1-en-3-one derivatives and pharmaceutical formulations thereof; useful for the treatment of alopecia, female hirsutism, seborrhea, and useful for the prevention of bone metastasis caused by prostatic cancer | |
NZ337048A (en) | Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer | |
IL133392A0 (en) | Benzo (5, 6) cyclohepta (1, 2b) pyridine derivatives useful for inhibition of farnesyl protein transferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |